Ashton Thomas Private Wealth LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Ashton Thomas Private Wealth LLC increased its holdings in Stryker Co. (NYSE:SYK - Free Report) by 17.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,166 shares of the medical technology company's stock after buying an additional 2,556 shares during the period. Ashton Thomas Private Wealth LLC's holdings in Stryker were worth $6,195,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp raised its position in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after purchasing an additional 316,404 shares in the last quarter. FMR LLC raised its position in Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock valued at $2,639,725,000 after purchasing an additional 215,782 shares in the last quarter. Geode Capital Management LLC raised its position in Stryker by 2.5% during the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock valued at $2,484,893,000 after purchasing an additional 165,490 shares in the last quarter. Parnassus Investments LLC acquired a new position in Stryker during the third quarter valued at approximately $762,798,000. Finally, Charles Schwab Investment Management Inc. raised its position in Stryker by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock valued at $714,715,000 after purchasing an additional 48,819 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Down 0.8 %

Shares of NYSE SYK traded down $3.03 during trading on Friday, hitting $379.28. 1,961,830 shares of the company traded hands, compared to its average volume of 1,209,637. The business's fifty day moving average is $382.45 and its 200 day moving average is $372.99. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market capitalization of $144.73 billion, a price-to-earnings ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 EPS. Equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker's dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

Several brokerages have commented on SYK. Stifel Nicolaus boosted their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Wells Fargo & Company boosted their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group boosted their target price on shares of Stryker from $384.00 to $427.00 and gave the stock a "neutral" rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.